Literature DB >> 3921437

Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent.

V Seltzer, S Vogl, B Kaplan.   

Abstract

Eleven women with advanced ovarian cancer treated postoperatively with combination chemotherapy (cytoxan, hexamethylmelamine, Adriamycin, and cis-platinum) had disease-free intervals of 5 to 46 months (mean: 22 months) and subsequently developed recurrent carcinoma. Each patient was then retreated with combination chemotherapy which included cis-platinum. There was a 72% response rate to retreatment (36% complete, 36% partial). These overall and complete remission rates are comparable to those of platinum-based combination chemotherapy in patients without prior treatment. Those patients who responded to retreatment had a significantly longer mean survival rate than those who did not.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3921437     DOI： 10.1016/0090-8258(85)90249-5

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


  9 in total

1.  Alterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy.

Authors:  Yayoi Kinoshita; Tamara Kalir; Jamal Rahaman; Peter Dottino; D Stave Kohtz
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

2.  Treatment of relapse of small cell lung cancer in selected patients with the initial combination chemotherapy carboplatin, etoposide, and epirubicin.

Authors:  P Collard; P Weynants; C Francis; D O Rodenstein
Journal:  Thorax       Date:  1992-05       Impact factor: 9.139

Review 3.  Rechallenging with anthracyclines and taxanes in metastatic breast cancer.

Authors:  Carlo Palmieri; Jonathan Krell; Colin R James; Catherine Harper-Wynne; Vivek Misra; Susan Cleator; David Miles
Journal:  Nat Rev Clin Oncol       Date:  2010-08-31       Impact factor: 66.675

Review 4.  Pharmacoeconomic considerations in treating ovarian cancer.

Authors:  D Bodurka-Bevers; C C Sun; D M Gershenson
Journal:  Pharmacoeconomics       Date:  2000-02       Impact factor: 4.981

Review 5.  History of intraperitoneal platinum drug delivery for ovarian cancer and its future applications.

Authors:  Franco Muggia; Andrea Bonetti
Journal:  Cancer Drug Resist       Date:  2021-06-19

Review 6.  Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.

Authors:  C R Lee; D Faulds
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 7.  Intraperitoneal therapy in the management of ovarian carcinoma.

Authors:  M Markman; T Hakes; B Reichman; W Hoskins; S Rubin; W Jones; L Almadones; J L Lewis
Journal:  Yale J Biol Med       Date:  1989 Jul-Aug

8.  Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer.

Authors:  M E L van der Burg; R de Wit; W L J van Putten; A Logmans; W H J Kruit; G Stoter; J Verweij
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

9.  Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group.

Authors:  A Buda; I Floriani; R Rossi; N Colombo; V Torri; P F Conte; R Fossati; A Ravaioli; C Mangioni
Journal:  Br J Cancer       Date:  2004-06-01       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.